Aim:To examine whether the existence of the donor-and recipient-derived DNA chimerism in recipient's plasma can be a predictive marker for the status of transplanted organ.Methods:One hundred and twenty-six female...Aim:To examine whether the existence of the donor-and recipient-derived DNA chimerism in recipient's plasma can be a predictive marker for the status of transplanted organ.Methods:One hundred and twenty-six female patients who had been transplanted with male kidneys were enrolled in the present study.In these female recipients,the SRY_Ⅰ, DYZ_I^(Ⅰst)and DYZ_Ⅰ^(2nd)genes on the Y chromosome from the plasma were prospectively examined using reverse tran- scription polymerase chain reaction(RT-PCR).Results:SRY,DYZ_Ⅰ^(Ⅰst)and DYZ_Ⅰ^(2nd)sequences were detected in the cell-free blood(plasma)of 97(77%)of 126 female patients with male kidney.The average time that the transplanted kidneys functioned was 8.7 years and 5.4 years among microchimerism-positive and microchimerism-negative recipients,respectively.The frequency of the patients who had acute rejection after renal transplantation was ap- proximately 10% and 28% in microchimerism-positive and microchimerism-negative recipients,respectively.Serum creatinine levels in microchimerism-positive patients were significantly lower than those in microchimerism-negative patients.Conclusion:These results suggest that plasma DNA microchimerism present in certain patients following renal transplantation and measurement of plasma DNA microchimerism using quantitative RT-PCR might be a useful predictor for the acceptance of transplanted kidneys.(Asian J Androl 2006 Jul;8:477-482)展开更多
目的:了解无偿献血人群乙型肝炎病毒(hepatitis B virus,HBV)感染情况,评估TMA技术应用于献血者HBV-DNA筛查的效果及其必要性。方法:采用平行检测ELISA/NAT模式,对2016年3月-2018年2月169160人(次)献血者及部分归队献血者进行常规血清学...目的:了解无偿献血人群乙型肝炎病毒(hepatitis B virus,HBV)感染情况,评估TMA技术应用于献血者HBV-DNA筛查的效果及其必要性。方法:采用平行检测ELISA/NAT模式,对2016年3月-2018年2月169160人(次)献血者及部分归队献血者进行常规血清学和NAT检测,对NAT筛查阳性标本行核酸鉴别试验;对单边试剂HBsAg+、HBV-DNA-献血者进行中和确证试验。结果:169160人(次)献血者中,双边试剂HBsAg检测阳性的为803例,占0.476%,单边试剂检测阳性的为243例,占0.144%。对40名HBV-DNA-、单边试剂检测HBsAg+标本经中和确证试验确证,仅有4名为阳性,确证阳性率为10%。检出1003例HBV-DNA+标本,HBsAg和HBV-DNA均为阳性的739例,2者一致率为73.7%。3种试剂阳性检出率比较有统计学差异(P<0.05);Murex试剂和新创试剂2种试剂检出阳性率有统计学差异(P<0.125)。2016年3月-2017年2月和2017年3月-2018年2月期间HBsAg-/HBV-DNA+检出率比较,没有统计学差异(P>0.05)。60名HBsAg-/HBV-DNA+归队献血者中有1名发生HBsAg阳转,该名献血者为HBV窗口期感染;其余59名献血者HBsAg阴性;HBVDNA检测显示,28名献血者HBV-DNA-,31名献血者HBV-DNA+,1名结果为不确定。结论:结合HBsAg检测,常规应用TMA技术检测HBV-DNA能缩短HBV感染的检测窗口期,检出HBV隐匿性感染,避免HBV漏检,从而有效地降低输血后传播乙型肝炎潜在风险。展开更多
文摘Aim:To examine whether the existence of the donor-and recipient-derived DNA chimerism in recipient's plasma can be a predictive marker for the status of transplanted organ.Methods:One hundred and twenty-six female patients who had been transplanted with male kidneys were enrolled in the present study.In these female recipients,the SRY_Ⅰ, DYZ_I^(Ⅰst)and DYZ_Ⅰ^(2nd)genes on the Y chromosome from the plasma were prospectively examined using reverse tran- scription polymerase chain reaction(RT-PCR).Results:SRY,DYZ_Ⅰ^(Ⅰst)and DYZ_Ⅰ^(2nd)sequences were detected in the cell-free blood(plasma)of 97(77%)of 126 female patients with male kidney.The average time that the transplanted kidneys functioned was 8.7 years and 5.4 years among microchimerism-positive and microchimerism-negative recipients,respectively.The frequency of the patients who had acute rejection after renal transplantation was ap- proximately 10% and 28% in microchimerism-positive and microchimerism-negative recipients,respectively.Serum creatinine levels in microchimerism-positive patients were significantly lower than those in microchimerism-negative patients.Conclusion:These results suggest that plasma DNA microchimerism present in certain patients following renal transplantation and measurement of plasma DNA microchimerism using quantitative RT-PCR might be a useful predictor for the acceptance of transplanted kidneys.(Asian J Androl 2006 Jul;8:477-482)
文摘目的:了解无偿献血人群乙型肝炎病毒(hepatitis B virus,HBV)感染情况,评估TMA技术应用于献血者HBV-DNA筛查的效果及其必要性。方法:采用平行检测ELISA/NAT模式,对2016年3月-2018年2月169160人(次)献血者及部分归队献血者进行常规血清学和NAT检测,对NAT筛查阳性标本行核酸鉴别试验;对单边试剂HBsAg+、HBV-DNA-献血者进行中和确证试验。结果:169160人(次)献血者中,双边试剂HBsAg检测阳性的为803例,占0.476%,单边试剂检测阳性的为243例,占0.144%。对40名HBV-DNA-、单边试剂检测HBsAg+标本经中和确证试验确证,仅有4名为阳性,确证阳性率为10%。检出1003例HBV-DNA+标本,HBsAg和HBV-DNA均为阳性的739例,2者一致率为73.7%。3种试剂阳性检出率比较有统计学差异(P<0.05);Murex试剂和新创试剂2种试剂检出阳性率有统计学差异(P<0.125)。2016年3月-2017年2月和2017年3月-2018年2月期间HBsAg-/HBV-DNA+检出率比较,没有统计学差异(P>0.05)。60名HBsAg-/HBV-DNA+归队献血者中有1名发生HBsAg阳转,该名献血者为HBV窗口期感染;其余59名献血者HBsAg阴性;HBVDNA检测显示,28名献血者HBV-DNA-,31名献血者HBV-DNA+,1名结果为不确定。结论:结合HBsAg检测,常规应用TMA技术检测HBV-DNA能缩短HBV感染的检测窗口期,检出HBV隐匿性感染,避免HBV漏检,从而有效地降低输血后传播乙型肝炎潜在风险。
